Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas?
stomach cancer signet ring cell carcinoma prognosis chemotherapy
- All consecutive patients taken care of, for a proven histologically adenocarcinoma
(ADCI and ADNCI) of the esophagus, the esogastric junction, or the stomach, in
surgical or medical oncology investigator centers, will be saved in a given database.
- For whom the first consultation took place between January 1997 and January 2010
- As they benefit from a medical and/or surgical support (primitive cancer being or not
resected), whatever the metastatic or the recurrence situation was.
- Histological type other than adenocarcinoma
- Other localization than esogastric junction, esophagus or stomach
Type of Study:
Observational Model: Case Control, Time Perspective: Retrospective
To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract
Outcome Time Frame:
participants are followed until death or time point at 31 september 2010
christophe mariette, MD, PhD
France: National Consultative Ethics Committee for Health and Life Sciences
- Signet Ring Cell Carcinoma
- Stomach Disease
- Case-control Study
- stomach disease
- signet ring cell carcinoma
- Stomach Diseases
- Carcinoma, Signet Ring Cell